Prothena Corp Public (PRTA) Non-Current Assets (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Non-Current Assets of $10.7 million for Q1 2026, down 81.93% year-over-year from $59.2 million in Q1 2025, and down 7.91% quarter-over-quarter from $11.6 million in Q4 2025.
Prothena Corp Public (PRTA) Non-Current Assets (2012 - 2026) Analysis & Trends
Prothena Corp Public's Non-Current Assets history runs 15 years deep, the most recent figure standing at $10.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 81.93% year-over-year to $10.7 million; the TTM figure through Mar 2026 stood at $10.7 million (down 81.93% YoY), while the FY2025 annual figure was $11.6 million, down 81.18% from the prior year.
- Non-Current Assets for Q1 2026 stood at $10.7 million, down from $11.6 million in the prior quarter.
- The five-year high for Non-Current Assets was $61.7 million in Q4 2024, with the low at $10.7 million in Q1 2026.
- The 5-year median for Non-Current Assets is $41.2 million (2023), against an average of $39.3 million.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets surged 88.49% in 2023, then tumbled 81.93% in 2026.
- Prothena Corp Public's Non-Current Assets stood at $38.9 million in 2022, then soared by 46.65% to $57.1 million in 2023, then rose by 8.05% to $61.7 million in 2024, then slumped by 81.18% to $11.6 million in 2025, then dropped by 7.91% to $10.7 million in 2026.
- Business Quant data shows PRTA's Non-Current Assets at $10.7 million in Q1 2026, $11.6 million in Q4 2025, and $12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | 10.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.57 Mn |
| Mar 31, 2026 | 10.69 Mn |
| Dec 31, 2025 | 11.61 Mn |
| Sep 30, 2025 | 12.65 Mn |
| Jun 30, 2025 | 13.59 Mn |
| Mar 31, 2025 | 59.16 Mn |
| Dec 31, 2024 | 61.70 Mn |
| Sep 30, 2024 | 60.27 Mn |
| Jun 30, 2024 | 59.59 Mn |
| Mar 31, 2024 | 57.33 Mn |
| Dec 31, 2023 | 57.10 Mn |
| Sep 30, 2023 | 56.32 Mn |
| Jun 30, 2023 | 43.55 Mn |
| Mar 31, 2023 | 41.24 Mn |
| Dec 31, 2022 | 38.94 Mn |
| Sep 30, 2022 | 29.88 Mn |
| Jun 30, 2022 | 28.30 Mn |
| Mar 31, 2022 | 25.79 Mn |
| Dec 31, 2021 | 24.56 Mn |
| Sep 30, 2021 | 25.17 Mn |